Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23093403 | 0.81 | MMP2 (0.39) | MEN1KMT2ASMN1; SMN2L3MBTL1MMP1 | |
| SCHEMBL29555276 | 0.80 | KDM4A (0.43) | L3MBTL1AAK1CTSSCTSK | |
| SCHEMBL23105713 | 0.80 | KDM4A (0.43) | L3MBTL1AAK1CTSSCTSK | |
| SCHEMBL30660472 | 0.79 | CA12 (0.43) | — | |
| SCHEMBL6629935 | 0.78 | L3MBTL1 (0.44) | L3MBTL1MMP1MMP2MMP9MMP12 | |
| SCHEMBL14448981 | 0.76 | ALDH1A1 (0.41) | KMT2ASMN1; SMN2L3MBTL1MMP1MMP2 | |
| SCHEMBL30881188 | 0.76 | ALDH1A1 (0.41) | KMT2ASMN1; SMN2L3MBTL1MMP1MMP2 | |
| SCHEMBL30681276 | 0.74 | DPP8 (0.40) | AAK1CTSSCTSK | |
| SCHEMBL28355512 | 0.74 | MGLL (0.52) | MEN1KMT2ASMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL29037153 | 0.73 | GRM5 (0.42) | L3MBTL1MMP1MMP2MMP9MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| EP-4217353-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | Ermium Therapeutics (FR) | 2023-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCR1, CXCL12 | MEN1 4670/4885KMT2A 4150/4885SMN1; SMN2 3965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.